Safety Outcomes of CXCR4 Antagonists for Stem Cell Mobilization in Patients with Multiple Myeloma

Key Points

• CXCR4 antagonists demonstrate favorable safety outcomes in multiple myeloma patients undergoing stem cell mobilization, suggesting a promising intervention.
• The study reports a strong safety profile, with adverse events recorded in less than 10% of participants during mobilization with CXCR4 antagonists.
• Observational analysis involved multiple myeloma patients, highlighting the safety of CXCR4 antagonists as future options for stem cell mobilization strategies.
• Results suggest further research is warranted, as findings may enable improved treatment protocols in stem cell mobilization for multiple myeloma.